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Background: The genetic model underlying a multifactorial disease such as coronary
artery disease (CAD) is complex as it embodies a potpourri of genes and environ-
mental factors. Accordingly, studies have averred that the polymorphisms in the
components of renin-angiotensin-aldosterone system are important in the development
and progression of CAD. We investigated relationship between b-ﬁbrinogen 455 G/A
gene polymorphism and CAD.
Methods: Sixty ﬁve patients with CAD (mean age 557years) and 65 patients with
normal coronary angiograms (mean age 517 years) were included in the study. The
types of b-ﬁbrinogen 455 G/A gene polymorphisms were analysed by polymerase
chain reaction and restriction fragment length polymorphism. For each polymorphic
position, one of three possible patterns may be obtained: Normal (GG) genotype,
heterozygous (GA), or homozygous (AA) mutant genotype. Demographic character-
istics and major risk factors for atherosclerosis were evaluated in the study groups.
Results: There was no signiﬁcant difference with respect to age and gender between
groups. The frequency of the GA heterozygous genotype was signiﬁcantly higher in
CAD group than controls (37 (%56.9) vs 25 (%38.5), p¼0.035). The frequency of the
AA homozygous mutant genotype was signiﬁcantly higher in CAD group than
controls (8 (%12.3) vs 1 (%1.5), p¼0.016). Between the two groups were compared
according to the dominant genetic model (GA+AA vs. GG), The number of patients
carrying at least one A mutant allele (GA+AA) were signiﬁcantly higher in CAD than
controls (45 (%69.2) vs 26 (%40), p¼0.001). With respect to allelic distribution (G vs
A, additive model), the frequency of the A mutant allele was signiﬁcantly higher in
CAD patients. (53 (%40.7) vs 27 (%20.7), p¼0.001).
Conclusions: In this study, we found that the frequency of b-ﬁbrinogen 455 G/A gene
polymorphism was higher in patients with CAD compared to control subject.
However, further large-sized studies are required for determining relationship between
b-ﬁbrinogen 455 G/A gene polymorphisms and CAD.General
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Aim: The effect of Vitamin D on cardiovascular health is controversial. Cardiac
syndrome X which is angina-like chest pain, a positive result from a stress test and
normal coronary arteries is encountered frequently in cardiology practice. Cardiac
syndrome X patients are frequently admitted to hospital. We investigated vitamin D
levels in cardiac syndrome X patients.
Methods: In all 95 patients (13 patients with cardiac syndrome X, 47 patients with
coronary artery disease and 35 control subjects) were enrolled. 25(OH) D3 levels were
measured in all participants in winter season. We compared vitamin D levels between
the groups.
Results: Vitamin D levels were different between the 3 groups (p<0.001). Vitamin D
levels were lower in patients with cardiac syndrome X than in controls (18.88.6 mg/
L vs. 30.116 mg/L; p<0.001) but vitamin D levels were similar in patients with
cardiac syndrome X and coronary artery disease (18.88.6 mg/L vs. 19.38.9 mg/L; P
NS) (Figure 1).JACC Vol 62/18/Suppl C j October 26–29, 2013 j TSC Abstracts/ORAConclusion: Vitamin D levels were reduced in cardiac syndrome X patients similarly
to with coronary artery disease. This suggests that vitamin D deﬁciency could inﬂu-
ence coronary ﬂow. Whether correction of Vitamin D deﬁciency can help to reduce
hospital admissions in patients with cardiac syndrome X and it needs to be studied
further.Coronary Heart Diseases
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Background: Metformin is a biguanid class, oral antidiabetic drug used in patients
with type 2 Diabetes Mellitus (DM). By increasing insulin sensitivity in tissues,
metformin mitigates insulin resistance which is the most important factor causing
endothelial dysfunction. It is known that metformin limits the infarct size after
myocardial infarction, reduces aneurysm development and remodeling in the ventricle
even in the prediabetic period. The current study was undertaken to assess the effects
of metformin therapy on coroner collateral development in type 2 diabetes patients.
Material-Methods: Study population consisted of 152 consecutive patients who have
undergone coronary angiography and who had at least one major coronary artery
stenosis of 95%. Coronary collateral circulations were graded from 0 to 3 according
to the Cohen-Rentrop method. And, collateral grading was classiﬁed as poor collateral
development when the collateral grade was 0 to 1, and as good collateral development
when the grade was 2 to 3. The effect of metformin therapy on the coronary collateral
growth was analyzed. Furthermore, patients taking metformin were divided into two
subgroups as high-dose (>1000 mg) and low-dose (1000 mg) patients. So, the effect
of the dosage of the drug on coronary collateral development was also assessed.
Results: The mean age of the study population was 65,249,71 years. 89 of the cases
(58,55%) were males, and 63 of them (41,45%) were females. No statistical difference
was determined between the groups’ demographic and laboratory characteristics.
Metformin therapy had no effect on coronary collateral development according to the
Rentrop classiﬁcation (p¼0,657). Correspondingly, good and poor coronary collateral
formations of the groups were similar (p¼0,837). 31 patients (63,30%) in the high-
dose metformin group were identiﬁed as having good collaterals, whereas only 7 cases
(31,80%) of the low-dose group had good collaterals. In conclusion, patients who
have used high-dose metformin had signiﬁcantly better coronary collaterals
(p¼0,014).
Conclusions: In our study, we have found that metformin therapy had no effect on the
development of coronary collaterals in the patients with type 2 DM. In contrast,
patients who were on high-dose metformin therapy had signiﬁcantly better coronary
collateral development. To the best of our knowledge, this is the ﬁrst study evaluating
the effects of metformin on coronary collateral formation. Finally, larger, prospective
studies are necessary to ﬁnd out the effects of metformin treatment on coronary
collateral development.LS C71
